Tien Lee | BiotechTV

top of page

Aardvark Therapeutics' approach to obesity is to inhibit hunger (vs appetite). It has a key pivotal trial scheduled to read in Prader-Willi syndrome next year, and is also working on weight loss

Founder and CEO Tien Lee describes how Aardvark's approach focuses on the gut-brain axis. Coverage brought to you by

Company News

5 days ago

Aardvark Therapeutics CEO Tien Lee on this month's $85M series C and leveraging TAS2R to modulate hunger and as a weight loss strategy

Tien Lee describes how TAS2R is a bitter taste receptor that naturally activates gut hormones and gut-brain signaling and can be used to dam

Company News

May 28, 2024

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Evaluate is a trusted provider of forecasting and commercial intelligence to the pharmaceutical industry. With a combination of gold standard data sources and deep pharma expertise, Evaluate helps clients make the right portfolio decisions to drive growth.

Evaluate's solutions provide a complete, dynamic view of development risk and commercial return across the full clinical lifecycle, underpinned by consensus forecasts to 2032, pipelines, deals and more. A consulting and analytics team is on always hand to help clients address unique clinical and commercial challenges.

Learn more about Evaluate

bottom of page

Aardvark Therapeutics' approach to obesity is to inhibit hunger (vs appetite). It has a key pivotal trial scheduled to read in Prader-Willi syndrome next year, and is also working on weight loss

Aardvark Therapeutics CEO Tien Lee on this month's $85M series C and leveraging TAS2R to modulate hunger and as a weight loss strategy

Follow BiotechTV

Sponsors

Sponsor Spotlight